RecruitingPhase 2NCT07229729

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

A Randomized, Open-label, Multicenter Phase II Clinical Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrollment

300 participants

Start Date

Nov 24, 2025

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called SHR-A2102 combined with other cancer treatments before and/or after surgery for people with non-small cell lung cancer that can be removed surgically. The goal is to see if adding this treatment improves outcomes. **You may be eligible if...** - You are between 18 and 70 years old - You have non-small cell lung cancer that can be surgically removed - You are in good overall health (ECOG score 0 or 1) - Your major organs (heart, kidneys, liver) are functioning well **You may NOT be eligible if...** - You are under 18 or over 70 years old - Your cancer has spread too far to be surgically removed - You have poor overall health or organ function - You are pregnant or breastfeeding - You have had certain prior treatments that would interfere with this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.